ALT - CIK 0001326190
Altimmune, Inc. (ALT) reported revenue of $41.00K for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $41.00K | +105.0% |
| FY 2024 | $20.00K | -95.3% |
| FY 2023 | $426.00K | +726.5% |
| FY 2022 | -$68.00K | -101.5% |
| FY 2021 | $4.41M | -46.1% |
| FY 2020 | $8.19M | +41.1% |
| FY 2019 | $5.80M | -43.8% |
| FY 2018 | $10.33M | -3.8% |
| FY 2017 |
Altimmune, Inc. (ALT) reported revenue of $41.00K for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2010 and fiscal 2025, Altimmune, Inc.'s revenue declined from $20.99M to $41.00K.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $10.74M |
| +231.8% |
| FY 2016 | $3.24M | -86.7% |
| FY 2011 | $24.27M | +15.6% |
| FY 2010 | $20.99M | - |